Table 4.
Incidence of PeINa by HPV type detected in the lesion among menb with the same HPV type detected at the genitals in the HIM Study
| HPV Typede | Incidence Ratec (95% CI) | Cumulative Incidence (%) | ||
|---|---|---|---|---|
| 6-Month (95% CI) | 12-Month (95% CI) | 24-Month (95% CI) | ||
| Any | 0.1 (0.1–0.2) | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) | 0.3 (0.1–0.4) |
| Vaccinef | 0.5 (0.2–0.9) | 0.5 (0.0–0.9) | 0.6 (0.1–1.1) | 1.3 (0.4–2.2) |
| High Risk | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) | 0.3 (0.0–0.6) |
| 16 | 0.7 (0.3–1.6) | 0.5 (0.1–2.1) | 0.5 (0.1–2.1) | 2.1 (0.9–5.2) |
| Low Risk | 0.1 (0.0–0.2) | 0.1 (0.0–0.3) | 0.2 (0.0–0.4) | 0.2 (0.0–0.4) |
| 6 | 0.3 (0.0–1.3) | 0.4 (0.1–2.9) | 0.9 (0.2–3.4) | 0.9 (0.2–3.4) |
| 11 | 0.6 (0.0–3.4) | 1.4 (0.2–9.2) | 1.4 (0.2–9.2) | 1.4 (0.2–9.2) |
| 73 | 0.4 (0.0–2.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) |
Abbreviation: PeIN- penile intraepithelial neoplasia, CI-confidence interval.
a
DNA detected using Linear Array.
b
Newly acquired-pathologically confirmed PeIN.
c
Incidence rate is cases per 1000 person-months.
d
Prevalent and incident genital HPV infection.
e
HPV types 18/31/33/35/39/45/51/52/56/58/59/68/26/40/53/54/66/69/71/70/82 did not progress to a PeIN lesion; therefore, incidence rates and cumulative incidence could not be calculated.
f
Vaccine HPV types 6/11/16/18